NASDAQ:KLDOKaleido Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kaleido Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.05 +0.05 (+0.71 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$6.97Now: $7.05▼$7.2250-Day Range$5.80MA: $6.69▼$8.0152-Week Range$2.82Now: $7.05▼$16.00Volume231,648 shsAverage Volume178,220 shsMarket Capitalization$214.95 millionP/E RatioN/ADividend YieldN/ABeta-0.04 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingKaleido Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Kaleido Biosciences has a potential upside of 13.5% from its current price of $7.05.Amount of Analyst CoverageKaleido Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesKaleido Biosciences has received 36 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKaleido Biosciences has received 54 “underperform” votes. (Add your “underperform” vote.)Community SentimentKaleido Biosciences has received 60.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote “Outperform” if you believe KLDO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKaleido Biosciences does not currently pay a dividend.Dividend GrowthKaleido Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kaleido Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $249,998.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of Kaleido Biosciences is held by insiders.Percentage Held by Institutions80.11% of the stock of Kaleido Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kaleido Biosciences are expected to decrease in the coming year, from ($2.13) to ($2.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kaleido Biosciences is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kaleido Biosciences is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 2.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KLDO Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees91 Outstanding Shares30,490,000Market Cap$214.95 million Next Earnings Date8/6/2020 (Estimated) OptionableNot Optionable NASDAQ:KLDO Rates by TradingView Receive KLDO News and Ratings via Email Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions How has Kaleido Biosciences' stock been impacted by COVID-19 (Coronavirus)? Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KLDO stock has increased by 27.3% and is now trading at $7.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kaleido Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kaleido Biosciences. When is Kaleido Biosciences' next earnings date? Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Kaleido Biosciences. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.64) EPS for the quarter, hitting the consensus estimate of ($0.64). View Kaleido Biosciences' earnings history. What price target have analysts set for KLDO? 2 analysts have issued 12 month price objectives for Kaleido Biosciences' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Kaleido Biosciences' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price. View analysts' price targets for Kaleido Biosciences. Has Kaleido Biosciences been receiving favorable news coverage? News stories about KLDO stock have trended somewhat positive on Saturday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kaleido Biosciences earned a news impact score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutKaleido Biosciences. Are investors shorting Kaleido Biosciences? Kaleido Biosciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,380,000 shares, an increase of 7.7% from the April 30th total of 2,210,000 shares. Based on an average trading volume of 121,800 shares, the days-to-cover ratio is currently 19.5 days. Currently, 24.4% of the shares of the stock are sold short. View Kaleido Biosciences' Current Options Chain. Who are some of Kaleido Biosciences' key competitors? Some companies that are related to Kaleido Biosciences include BELLUS Health (BLU), Orthopediatrics (KIDS), Krystal Biotech (KRYS), Heska (HSKA), Inogen (INGN), Rhythm Pharmaceuticals (RYTM), Enerplus (ERF), Gossamer Bio (GOSS), Trillium Therapeutics (TRIL), Stoke Therapeutics (STOK), BellRing Brands (BRBR), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Omeros (OMER) and Avrobio (AVRO). View all competitors. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), QUALCOMM (QCOM) and Exxon Mobil (XOM). Who are Kaleido Biosciences' key executives? Kaleido Biosciences' management team includes the following people: Mr. Michael W. Bonney, Exec. Chair (Age 62, Pay $397.5k)Ms. Alison Lawton, CEO, Pres & Director (Age 59, Pay $1.04M)Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 39, Pay $35k)Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 41, Pay $464.81k)Dr. Katharine Knobil M.D., Chief Medical Officer and Head of R&D (Age 55, Pay $868.03k) When did Kaleido Biosciences IPO? (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Kaleido Biosciences' stock symbol? Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO." Who are Kaleido Biosciences' major shareholders? Kaleido Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.84%), State Street Corp (0.48%), Geode Capital Management LLC (0.43%), Victory Capital Management Inc. (0.41%), Victory Capital Management Inc. (0.41%) and Invesco Ltd. (0.27%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney and Ventures Fund V LP Flagship. View institutional ownership trends for Kaleido Biosciences. Which institutional investors are selling Kaleido Biosciences stock? KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors, Morgan Stanley, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Kaleido Biosciences. Which institutional investors are buying Kaleido Biosciences stock? KLDO stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Nuveen Asset Management LLC, State Street Corp, Geode Capital Management LLC, Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, and Citigroup Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, and Ventures Fund V LP Flagship. View insider buying and selling activity for Kaleido Biosciences. How do I buy shares of Kaleido Biosciences? Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kaleido Biosciences' stock price today? One share of KLDO stock can currently be purchased for approximately $7.05. How big of a company is Kaleido Biosciences? Kaleido Biosciences has a market capitalization of $214.95 million. Kaleido Biosciences employs 91 workers across the globe. This page was last updated on 6/6/2020 by MarketBeat.com Staff
